The objective of the pilot is to confirm that the sharing of this information can facilitate the marketing authorisation process by the participating non-EEA regulators.
Under the pilot, an application for a marketing authorisation submitted in the framework of a DCP will be submitted concomitantly to the TGA. Medicines will continue to be approved for supply within Australia on the basis of a decision by a TGA delegate, and all medicine applications will continue to receive the same level of scrutiny by TGA evaluators.
Our participation in the pilot offers applicants the potential to obtain market authorisation in a number of chosen markets as part of a coordinated process. Experience gained by industry and regulatory agencies will also help to inform other international information and work sharing models currently under consideration by the TGA and collaborating agencies.
Expression of Interest for generic drug applicants
The TGA encourages generic drug manufacturers to consider participating in this ground-breaking pilot. The Expression of Interest (EOI) can be downloaded.
Please note that the Therapeutic Goods Administration is not the author of this document.
Responses to this EOI are requested by 10 October 2014.
The enclosed EOI provides operational details for the pilot including:
List of eligibility criteria.
EOI request form to participate in the pilot. The form includes a section seeking consent from sponsors for the EU DCP to share assessment reports with pilot participants and other IGDRP member agencies of the sponsor's choosing in real time.
Contact information at participating regulatory agencies.
Public Statement for the ACSS Generics Working Group face to face meetings, Strasbourg, France, 6-7 May 2016
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.